Suzuki Yusuke, Suzuki Hitoshi, Nakata Junichiro, Sato Daisuke, Kajiyama Tadahiro, Watanabe Tomonari, Tomino Yasuhiko
Division of Nephrology, Department of Internal Medicine, Juntendo University Faculty of Medicine, Hongo 2-1-1, Bunkyo-ku, Tokyo 113-8421, Japan.
Clin Dev Immunol. 2011;2011:639074. doi: 10.1155/2011/639074. Epub 2011 Jul 18.
Although impaired immune regulation along the mucosa-bone marrow axis has been postulated to play an important role, the pathogenesis of IgA nephropathy (IgAN) is unknown; thus, no disease-specific therapy for this disease exists. The therapeutic efficacy of tonsillectomy or tonsillectomy in combination with steroid pulse therapy for IgAN has been discussed. Although randomized control trials for these therapies are ongoing in Japan, the scientific rationale for these therapies remains obscure. It is now widely accepted that abnormally glycosylated IgA1 and its related immune complex (IC) are probably key molecules for the pathogenesis, and are thus considered possible noninvasive biomarkers for this disease. Emerging evidence indicates that B cells in mucosal infections, particularly in tonsillitis, may produce the nephritogenic IgA. In this paper, we briefly summarize characteristics of the nephritogenic IgA/IgA IC, responsible B cells, and underlying mechanisms. This clinical and experimental information may provide important clues for a therapeutic rationale.
尽管推测黏膜-骨髓轴免疫调节受损发挥了重要作用,但IgA肾病(IgAN)的发病机制尚不清楚;因此,目前尚无针对该疾病的特异性治疗方法。扁桃体切除术或扁桃体切除术联合类固醇脉冲疗法对IgAN的治疗效果已被讨论。尽管日本正在进行这些疗法的随机对照试验,但这些疗法的科学依据仍不明确。现在人们普遍认为,异常糖基化的IgA1及其相关免疫复合物(IC)可能是发病机制的关键分子,因此被认为是该疾病可能的非侵入性生物标志物。新出现的证据表明,黏膜感染中的B细胞,特别是扁桃体炎中的B细胞,可能产生致肾炎性IgA。在本文中,我们简要总结了致肾炎性IgA/IgA IC、相关B细胞的特征及潜在机制。这些临床和实验信息可能为治疗原理提供重要线索。